Hervé Brailly is the Chairman of the Supervisory Board of Innate Pharma, a French biotechnology company he co-founded in 1999 and where he served as CEO until end of 2016.
Hervé Brailly was previously a researcher at Immunotech SA, a biotechnology start up acquired in 1995 by Beckman-Coulter, where he was notably in charge of the growth of the business activities in China.
Since 2017, he is member of the Board of Deinove, a French biotechnology company. Hervé Brailly is also notably member of the development council of the ”Marseille Provence Metropole”, the Strategy and Prospects Committee of Aix Marseille University and the Investment Committee of SATT Sud Est. He is also President of the engineering school Polytech-Marseille (Aix Marseille Université), and a member of the Executive committee and treasury of Eurobiomed, the catalyst of the health sector of the southern France.
Hervé Brailly is graduated of the Ecole des Mines de Paris (1983) and a Doctor of Immunology, with a specialization in immuno-pharmacology.